You are here:
Following the latest application round for new and underused vaccine support, GAVI's Executive Committee has approved applications from 37 countries: 16 for rotavirus vaccines, 18 for pneumococcal vaccines, five for pentavalent vaccine, nine for measles 2nd dose and four for meningitis A vaccine.
The roll out of rotavirus and pneumococcal vaccines has already started: a major step towards protecting children against severe diarrhoea and pneumonia, the two leading child killers.
GAVI plans to support the rollout of pneumococcal vaccines in over 40 countries by 2015.
Ten GAVI-eligible countries have added rotavirus vaccine to their immunisation programmes.
MenAfriVac vaccine could prevent 150,000 deaths by 2015 in Africa's "meningitis belt".
GAVI supports the Measles Initiative and a second round of measles vaccination jabs.
GAVI-funded rubella vaccines are now combined for easy delivery with measles vaccines in a single measles-rubella shot.
GAVI funds routine immunisation programmes and vaccine stockpiles for preventive campaigns.
Safe and effective human papillomarivus vaccines offer protection against 70% of all cervical cancer cases.
By 2015 GAVI aims to have supported the vaccination of 270 million children with pentavalent vaccine.
There is no limit to the number of vaccines that a country can apply for in a single application round, but only one vaccine per country will be funded in a single round and applicants must propose an introduction date within two years of the actual application round.
Countries can also request support for the partial introduction of a vaccine or a phased rollout. In addition, GAVI funds auto-disable syringes and safety boxes, sent to successful country applicants together with the vaccines.
All countries must co-finance GAVI-supported vaccines, except for measles second dose and preventative campaigns for yellow fever and meningitis A; in no case will GAVI support replace government funds already allocated for the purchase of vaccines.
Initially, the NVS programme provided five-year support grants with the expectation that countries would cover continued vaccination cost after GAVI’s support ended. This assumed that GAVI’s business model would drive down the price of vaccines within five years to the point where poor countries could afford to pay themselves. When it became apparent that vaccine prices were not dropping quickly enough, GAVI revised its support timelines to be based on country planning cycles.
Today, countries can only request NVS support for the duration of comprehensive Multi-Year Plans for immunization – this ensurs that vaccine rollouts are aligned with the national health and budgetary planning process.
Forty-three percent of GAVI vaccines are produced by pharmaceutical companies based in emerging markets.
© GAVI Alliance 2013
modal window here